The Obama administration is using its last few days in office to address a number of data privacy issues—most recently releasing a final rule that lifts a burden on scientists working with human subjects.
BioMotiv, a Cleveland-based drug development accelerator associated with The Harrington Project, and a university in New Zealand have announced the formation of an immuno-oncology startup that will work to develop a suite of cancer vaccines.
McKesson Corp. has agreed to pay a record $150 million civil penalty and suspend sales of controlled substances from distribution centers in four states over allegations that it has once again failed to detect and report suspicious orders of controlled substances.
Baxter Healthcare Corp. is settling allegations that it failed to follow proper federal standards when manufacturing sterile drug products between 2011 and 2012 at a factory in Marion, N.C.
Ireland-based Shire Pharmaceuticals has agreed to pay $350 million to settle allegations that it bribed clinics and physicians to use its diabetic ulcer treatment.
In a press conference Wednesday, President-elect Donald Trump also said pharmaceutical companies are "getting away with murder" and that a plan to replace the Affordable Care Act will be given "essentially simultaneously" with repeal actions.
Healthcare giant Johnson & Johnson plans next month to disclose price increases of its prescription drugs as the industry tries to calm the storm over soaring prices.
Approvals for new drugs dropped to a six-year low in 2016. Industry insiders are optimistic that the recently passed 21st Century Cures Act will speed up the process.
The Obama administration has finalized a rule that imposes fines on drug companies that overcharge hospitals and clinics for medication purchased under the government's 340B drug discount program.
2017 will be a year of challenge and opportunity for the pharmaceutical and medical device industries thanks to the 21st Century Cures Act, which passed with their vigorous lobbying support.
Insurers, providers, policymakers, employers and consumer groups spent much of 2016 blasting the pharmaceutical industry's pricing of prescription drugs.
The launch of Mylan's long-promised generic alternative is expected to still generate millions of dollars in revenue for the drugmaker while also protecting its market share against current and future competition.